Regardless of the sequential decrease in Current Liabilities, during the third quarter 2026, Quick Ratio deteriorated to 6.12 above company average Quick Ratio.

Within Major Pharmaceutical Preparations industry 145 other companies have achieved higher Quick Ratio than Cartesian Therapeutics Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 434 to 626.

Explain Quick Ratio?
How much Cash & cash equivalents RNAC�s has?
What are RNAC�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/RNAC/financial-strength

https://api.csimarket.com/api/v1/companies/RNAC/fundamentals

https://api.csimarket.com/api/v1/companies/RNAC/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

RNAC Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	45.53 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-14.23 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	6.12	Subscribe	Subscribe	Subscribe	Subscribe
RNAC's Total Ranking	# 626	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-2.25 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-16.69 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 146
Healthcare Sector	# 230
Overall Market	# 626

Quick Ratio Statistics
High	Average	Low
13.08	5.07	0.36
(Jun 30 2025)		(Jun 30 2019)

Financial Statements
Cartesian Therapeutics Inc 's Current Liabilities	$ 20 Millions	Visit RNAC's Balance sheet
Cartesian Therapeutics Inc 's Cash & cash equivalent	$ 123 Millions	Visit RNAC's Balance sheet
Source of RNAC's Sales		Visit RNAC's Sales by Geography

Cumulative Cartesian Therapeutics Inc 's Quick Ratio

RNAC's Quick Ratio for the trailling 12 Months

RNAC Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	11.69 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-26.18 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	7.19	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3368	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	9.63 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-3.82 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to RNAC Financial Strength Comparisons >> Go to Compare RNAC Quick Ratio to its Competitors

News about Cartesian Therapeutics Inc Quick Ratio

Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing

In a recent announcement, Cartesian Therapeutics, a clinical-stage biotechnology company focusing on mRNA cell therapy for autoimmune diseases, revealed that it has entered into a securities purchase agreement for private investment in public equity (PIPE) financing. The company expects to generate approximately $130.0 million in gross proceeds from this financing, which is scheduled to conclude on or around July 3, 2024, subject to customary closing conditions. This infusion of funds is anticipated to further bolster the company s research and development efforts in the field of autoimmune diseases.
Key Facts:
1. Cartesian Therapeutics, Inc. (NASDAQ: RNAC) has secured a private investment in public equity (PIPE) financing, resulting in an estimated $130.0 million in gross proceeds.
2. The financing agreement is subject to customary closing conditions and is expected to conclude on or about July 3, 2024.
3. The funds raised through this financing will provide Cartesian Therapeutics with the necessary resources to advance its mRNA cell therapy for autoimmune diseases.
4. Cartesian Therapeutics seeks to pioneer innovative solutions that address the complex challenges associated with autoimmune conditions.
5. The company aims to leverage mRNA-based cell therapies to develop personalized treatment options for a wide range of autoimmune diseases.
6. Cartesian Therapeutics has demonstrated significant growth in cash and cash equivalents, which increased by 34.46% in the first quarter of 2024 compared to the previous quarter.
7. The company s current liabilities decreased during this period, leading to an improved quick ratio of 2.82, indicating a strong ability to meet short-term obligations.
8. While Cartesian Therapeutics ranks higher in quick ratio compared to the fourth quarter of 2023, it is important to note that 146 other companies within the industry have achieved higher quick ratios in the first quarter of 2024.
9. Looking at the trailing twelve months, Cartesian Therapeutics quick ratio dropped slightly to 2.41, still above the company s trailing twelve months average.
10. Comparative analysis reveals that other companies in the industry have achieved superior quick ratios over the past twelve months, resulting in Cartesian Therapeutics overall ranking declining from 1711 in the fourth quarter of 2023 to 2473.

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q3 2026 to $20.09 millions, cumulative Quick Ratio decreased to 7.19 above the RNAC average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 415 other companies have achieved higher Quick Ratio than Cartesian Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 3368, from total ranking during the twelve months ending second quarter 2026 at 3371.

Explain Quick Ratio?
How much Cash & cash equivalents RNAC�s has?
What are RNAC�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 416
Healthcare Sector	# 847
Within the Market	# 3368

trailing twelve months Quick Ratio Statistics
High	Average	Low
10.88	4.14	0.69
(Dec 31 2025)		(Dec 31 2019)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Keros Therapeutics Inc	16.36	$ 259.464 Millions	$ 15.858 Millions
Design Therapeutics Inc	16.36	$ 208.608 Millions	$ 12.753 Millions
Whitehawk Therapeutics Inc	16.25	$ 169.672 Millions	$ 10.441 Millions
Palvella Therapeutics Inc	15.85	$ 236.680 Millions	$ 14.928 Millions
Avalo Therapeutics Inc	15.63	$ 392.966 Millions	$ 25.135 Millions
Bioage Labs Inc	14.91	$ 283.637 Millions	$ 19.027 Millions
Damora Therapeutics Inc	14.72	$ 528.478 Millions	$ 35.892 Millions
Sellas Life Sciences Group Inc	14.51	$ 134.711 Millions	$ 9.286 Millions
Protagonist Therapeutics inc	14.42	$ 800.064 Millions	$ 55.464 Millions
Praxis Precision Medicines Inc	14.20	$ 745.323 Millions	$ 52.498 Millions
Tenax Therapeutics Inc	13.61	$ 113.700 Millions	$ 8.355 Millions
Ensysce Biosciences Inc	13.56	$ 29.671 Millions	$ 2.189 Millions
Corvus Pharmaceuticals Inc	13.25	$ 204.252 Millions	$ 15.418 Millions
Erasca Inc	13.10	$ 643.696 Millions	$ 49.122 Millions
Stablecoin Development Corporation	13.01	$ 7.153 Millions	$ 0.550 Millions
Uniqure N v	12.78	$ 768.430 Millions	$ 60.142 Millions
Rhythm Pharmaceuticals Inc	12.62	$ 320.944 Millions	$ 25.438 Millions
Assembly Biosciences Inc	12.61	$ 314.262 Millions	$ 24.921 Millions
Dyne Therapeutics Inc	12.53	$ 1,134.386 Millions	$ 90.545 Millions
Sensei Biotherapeutics Inc	12.44	$ 174.795 Millions	$ 14.049 Millions
Crescent Biopharma Inc	12.32	$ 289.357 Millions	$ 23.490 Millions
Spyre Therapeutics Inc	12.24	$ 82.727 Millions	$ 6.760 Millions
Edgewise Therapeutics inc	12.10	$ 1,743.893 Millions	$ 144.106 Millions
Obsidian Therapeutics, Inc.	11.77	$ 214.905 Millions	$ 18.264 Millions
Structure Therapeutics Inc	11.62	$ 1,244.661 Millions	$ 107.104 Millions
Immunome Inc	11.27	$ 461.582 Millions	$ 40.966 Millions
Korro Bio Inc	11.06	$ 165.015 Millions	$ 14.923 Millions
Xenon Pharmaceuticals Inc	10.99	$ 950.798 Millions	$ 86.487 Millions
Newamsterdam Pharma Company N v	10.99	$ 628.242 Millions	$ 57.154 Millions
Vtv Therapeutics Inc	10.99	$ 77.164 Millions	$ 7.024 Millions

Date modified: 2026-11-06T09:20:02+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.